Palbociclib in Hormone Receptor Positive Advanced Breast Cancer

被引：0
作者：
Vozy, A. [1 ]
Delaloge, S. [1 ]
机构：
[1] Inst Gustave Roussy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France
来源：
ONCOLOGIE | 2016年 / 18卷 / 01期
关键词：
4/6; INHIBITOR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 80
页数：2
相关论文
共 2 条
  • [1] CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
    DeMichele, Angela
    Clark, Amy S.
    Tan, Kay See
    Heitjan, Daniel F.
    Gramlich, Kristi
    Gallagher, Maryann
    Lal, Priti
    Feldman, Michael
    Zhang, Paul
    Colameco, Christopher
    Lewis, David
    Langer, Melissa
    Goodman, Noah
    Domchek, Susan
    Gogineni, Keerthi
    Rosen, Mark
    Fox, Kevin
    O'Dwyer, Peter
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (05) : 995 - 1001
  • [2] PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    Finn, Richard S.
    Dering, Judy
    Conklin, Dylan
    Kalous, Ondrej
    Cohen, David J.
    Desai, Amrita J.
    Ginther, Charles
    Atefi, Mohammad
    Chen, Isan
    Fowst, Camilla
    Los, Gerret
    Slamon, Dennis J.
    [J]. BREAST CANCER RESEARCH, 2009, 11 (05)
1